Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer.
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020 04 01; 12(537).